Maraviroc observational study: The impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients

AIDS Research and Human Retroviruses

Volumn 29, Issue 1, 2013, Pages 105-111

  Willig, James H ^a   Wilkins, Sara Anne ^a   Tamhane, Ashutosh ^b   Nevin, Christa R ^a   Mugavero, Michael J ^a   Raper, James L ^a   Napolitano, Laura A ^c   Saag, Michael S ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; ETRAVIRINE; MARAVIROC; RALTEGRAVIR; RITONAVIR;

ADULT; ALCOHOL ABUSE; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ANXIETY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DEPRESSION; DRUG FORMULARY; DRUG INDUSTRY; DRUG INFORMATION; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; GENOTYPE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INSURANCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; OBSERVATIONAL STUDY; PHENOTYPE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SALVAGE THERAPY; SMOKING; SUBSTANCE ABUSE; VIRAL TROPISM; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; HIV; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; SALVAGE THERAPY; TREATMENT FAILURE; TRIAZOLES;

EID: 84871889866     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0157     Document Type: Article

References (17)

1. Clotet B, et al.: Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007;369(9568): 1169-1178.
2. Arasteh K, et al.: Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther 2009;14(6):859-864.
3. Gulick RM, et al.: Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359(14): 1429-1441.
4. Hardy WD, et al.: Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5- tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010;55(5): 558-564.
5. Steigbigel RT, et al.: Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359(4):339-354.
6. Steigbigel RT, et al.: Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: Week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010;50(4):605-612.
7. Lazzarin A, et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET- 2: 24-week results from a randomised, double-blind, placebo- controlled trial. Lancet 2007;370(9581):39-48.
8. Madruga JV, et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):29-38.
9. Asmuth DM, et al.: CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010;54(4):394-397.
10. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. Department of Health and Human Services, p. 1-166.
11. Parra J, et al.: Clinical utility of maraviroc. Clin Drug Invest 2011;31(8):527-542.
12. KRC Research: Physicians' Opinions About Pharmaceutical and Biotech Research Company Activities and Information. 2008, KRC Research.
13. Rhee SY, et al.: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003;31(1):298-303.
14. Shafer RW: Rationale and uses of a public HIV drug-resistance database. J Infect Dis 2006;194(Suppl 1):S51-58.
15. De Luca A, et al.: Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003;187(12):1934-1943.
16. Liu TF and Shafer RW: Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42(11):1608-1618.
17. Hogg RS, et al.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279(6):450-454.